Screener
Vertex Pharmaceuticals VRTX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's other non-current liabilities?
- Vertex Pharmaceuticals (VRTX) reported other non-current liabilities of $1.26B in Q2 2026.
- How has Vertex Pharmaceuticals's other non-current liabilities changed year-over-year?
- Vertex Pharmaceuticals's other non-current liabilities increased by 5.4% year-over-year, from $1.2B to $1.26B.
- What is the long-term trend for Vertex Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's other non-current liabilities has grown at a 63.6% compound annual growth rate (CAGR), from $108.4M to $1.27B.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Vertex Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude